

This promotional material has been developed and funded by Bayer plc and is intended for UK healthcare professionals (HCPs) only.

Prescribing Information and Adverse Event Reporting for Beyontra®▼ (acoramidis) can be found at the bottom of the page.



Suspect **ATTR-CM** in your daily practice

Reporting adverse events and quality complaints

Adverse events should be reported. Reporting forms and information can be found at <http://www.mhra.gov.uk/yellowcard>. Adverse events should also be reported to Bayer plc.

If you want to report an adverse event or quality complaint, reports can be directed to:
Tel: 01182063500 or email: pvuk@bayer.com

Further information is available on the "contact" tab at www.bayer.co.uk.

Prescribing Information and adverse event reporting are available by scanning the QR code or visiting this [link](#).



Red flags raising early suspicion of ATTR-CM

A left ventricular (LV) wall thickness of 12 mm or greater, combined with the presence of one or more red flags, should prompt consideration of ATTR-CM.¹



*LV wall thickness **≥12 mm?** + **≥1 Red Flag** = **Suspect cardiac amyloidosis**

*Women have naturally thinner septal walls; the ≥12mm ATTR-CM cutoff may delay diagnosis if applied without sex-specific consideration.³

Patient identifier

To learn more about ATTR-CM, please click [here](#) or scan the QR code to visit BayerPRO



Red flag checklist ^{1,2}		✓
» LV wall thickness ≥12 mm?		
Cardiac	Heart failure or aortic stenosis (≥65 years)	
	Hypotensive or normotensive if previously hypertensive	
	Unresponsive/intolerant to standard HF therapies	
	Possible family history of ATTR-CM	
Musculoskeletal	Bilateral carpal tunnel syndrome	
	Ruptured biceps tendon	
	Lumbar spinal stenosis	
	Trigger finger	
Nervous system	Peripheral polyneuropathy	
	Sensory involvement	
	Autonomic dysfunction	
	Muscle weakness	
ECG	Reduced QRS voltage to mass ratio	
	Pseudo Q waves	
	AV conduction disease	
Echo/CMR	Reduced longitudinal strain with apical sparing	
	Subendocardial/transmural LGE	
	Increased extracellular volume	
	Aortic stenosis	
	Grade 2 or worse diastolic dysfunction	
Laboratory findings	Elevated BNP/ NT-proBNP	
	Persistent low-level increase in troponin	

» Consider investigation for ATTR-CM

Early recognition and prompt diagnosis and treatment initiation can make a meaningful difference to your patient's outcome.

ATTR-CM, transthyretin amyloid cardiomyopathy; **AV**, atrio-ventricular; **BNP**, b-type natriuretic peptide; **CMR**, cardiac magnetic resonance; **ECG**, electrocardiogram; **HF**, heart failure; **LGE**, late gadolinium enhancement; **LV**, left ventricular; **NT-proBNP**, N-terminal pro b-type natriuretic peptide.
References: 1. Garcia-Pavia P, et al. Eur J Heart Fail. 2021;23(4):512–526. 2. Ioannou A, et al. Eur Heart J. 2023;44(31):2893–2907. 3. Vogel J, et al. Eur Heart J. 2025;46(Suppl 1):1006.